Leriglitazone halts disease progression in adult patients with early cerebral adrenoleukodystrophy in compassionate-use study published in Brain

News | 06. 11. 2024


Mataró, Barcelona, Spain, 11 June, 2024 - Minoryx Therapeutics today announced that results from a compassionate use study of leriglitazone for treatment of progressive cerebral adrenoleukodystrophy (cALD) in adult male patients, published1 in the peer-reviewed journal Brain.